You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


NICE recommendation for AbbVie’s Rinvoq

AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has delivered a positive Final Draft Guidance (FDG) recommending its Rinvoq therapy for the treatment of moderately to severely active Crohn’s disease.